



Pfizer Announces a [Research Grant RFP](#)

Alopecia Areata, Atopic Dermatitis and Vitiligo (Global)

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

II. Eligibility

Geographic Scope:	Global (including U.S.A.)
Applicant Eligibility Criteria	<ul style="list-style-type: none"> • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. • Applicant must be affiliated with a host institution

III. Requirements

Date RFP Issued	<ul style="list-style-type: none"> • July 12, 2021
Clinical Area	<ul style="list-style-type: none"> • Alopecia Areata, Atopic Dermatitis, and Vitiligo
General Area of Interest for this RFP:	<p>The intent of this RFP is to support preclinical, clinical and outcomes research through a competitive grant program to increase medical knowledge in Alopecia Areata, Atopic Dermatitis, and/or Vitiligo. Please note that research focusing on Alopecia Areata and Atopic Dermatitis is of higher priority than Vitiligo at this time, and grants will be distributed accordingly.</p> <p>Areas of Research Focus</p> <ul style="list-style-type: none"> • Alopecia Areata (AA) - Research proposals with the primary objective to increase the understanding of the role of the TEC family kinases and JAK3 kinase in the pathogenesis of AA, as well as the impact of their downregulation or inhibition. • Atopic Dermatitis (AD) - Research and new insights into (1) the role of JAK-STAT pathway and inhibition in AD, (2) the various phenotypes/endotypes in AD, (3) factors influencing barrier function and repair, (4) the influence of the skin and gut microbiome in AD, (5) the factors influencing AD flares, and (6) the impact of Covid-19 on patients with AD. • Vitiligo (Viti) - Research proposals with the primary objective to increase the understanding of the role of the TEC family kinases and JAK3 kinase in the pathogenesis of Viti, as well as the impact of their downregulation or inhibition.

	<p>Out of Scope</p> <ul style="list-style-type: none"> • Research proposals that conflict with ongoing Pfizer-sponsored trials or future development plans • Research proposals that require drug supply for investigational JAK-inhibitors
<p>Expected Approximate Monetary Range of Grant Applications:</p>	<ul style="list-style-type: none"> • Individual projects requesting up to \$175,000 (USD) will be considered. Pfizer anticipates awarding up to 15 grants.
<p>Key Dates:</p>	<ul style="list-style-type: none"> • RFP release date: July 12, 2021 • Grant Application due date: August 16, 2021 • Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5) • Anticipated Grant Award Notification Date: September 2021 • Grants will be distributed following a fully executed agreement • Anticipated Project Start and End Dates: On or after contract execution, anticipated before December 31, 2021
<p>How to Submit:</p>	<ul style="list-style-type: none"> • Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. • In the application: <ul style="list-style-type: none"> ○ For the question “Competitive Grant?” select Yes ○ Select the following Competitive Grant Program Name: 2021 I&I G Inflammatory and Immune-Mediated Dermatologic Disorders • Requirements for submission: <ul style="list-style-type: none"> ○ Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field. ○ If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed.</p>
<p>Questions:</p>	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Solis (Amanda.Solis@pfizer.com), with the subject line “Inflammatory and Immune-Mediated Dermatologic Disorders (Global) July 2021.” • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program

Grant Agreements:	<ul style="list-style-type: none">• If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.• Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.• The agreement is expected to be signed by both parties within 2021 and without changes or negotiations. If organizations cannot agree to the terms before year end, the grant may be canceled.
Review and Approval Process:	<ul style="list-style-type: none">• Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
Mechanism by which Applicants will be Notified:	<ul style="list-style-type: none">• All applicants will be notified via email by the dates noted above.• Applicants may be asked for additional clarification during the review period.

Appendix A

General RFP Submission Requirements

Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives:	<ul style="list-style-type: none"> Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective
Assessment of Need for the Project:	<ul style="list-style-type: none"> This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question
Target Audience:	<ul style="list-style-type: none"> Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods:	<ul style="list-style-type: none"> Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan
Innovation:	<ul style="list-style-type: none"> Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project
Evaluation and Outcomes:	<ul style="list-style-type: none"> Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines
Anticipated Project Timeline:	<ul style="list-style-type: none"> Provide an anticipated timeline for your project including project start/end dates
Additional Information:	<ul style="list-style-type: none"> If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail:	<ul style="list-style-type: none">• This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project
References:	<ul style="list-style-type: none">• Bibliography of relevant references.